Chairman of the Executive Board/CEO
Bio
Peter Goldschmidt has been CEO of STADA Arzneimittel AG since 1 September 2018; following the PE takeover by Bain Capital and Cinven. In this role, he has transformed STADA from a German-centred company, known mainly as a generics supplier, into a broad-based international healthcare company with superior growth above market on the top and bottom line. STADA is today the partner of choice and leader in many countries in its 3 business segments: Consumer Healthcare, Generics and Specialty medicines.
Under Goldschmidt’s leadership, STADA has become the fastest-growing player within the world’s TOP-10 consumer healthcare companies in 2023. STADA consistently outperforms its peers in the generics sector, and is a rapidly growing supplier in specialty pharmaceuticals, with an extensive portfolio and pipeline of biosimilars complemented by innovative and orphan therapies in therapeutic categories including nephrology and Parkinson’s disease. Through this breadth of portfolio, STADA is able to offer patients and their caregivers an extensive range of solutions for the vast majority of health conditions.
This outstanding performance ahead of industry norms has been driven by a unique growth culture. The success of this cultural transformation, which has been underpinned by clear corporate values, purpose and vision, has been confirmed consistently by results from regular employee surveys that show engagement far above industry norms.
Among the highlights of Goldschmidt’s leadership has been transforming a classically conservative company into a modern, progressive employer. The proportion of women in leadership roles exceeds 50%, and 88 different nationalities across the organization is testament to how STADA now attracts top talent from around the world. STADA’s position among the pharma industry’s most sustainable companies has been confirmed by external leading agencies.
Over a career spanning almost 35 years, Goldschmidt has gained extensive experience across the pharmaceutical industry, including innovative, off-patent and consumer healthcare medicines. He has held senior leadership positions in Europe, North America and Asia, including between 2013 and 2018 as President of Sandoz US and Head of North America.
